Improving Health, Improving Lives
NHS Calderdale Clinical Commissioning Group Logo

Bisphosphonates, Faslodex, Reconstructive Breast Surgery (1718015)

Part A – Provision of bisphosphonates

1. Is your CCG routinely funding the provision of bisphosphonates for all eligible women to reduce the risk of their primary breast cancer spreading to other parts of the body? Eligible women are defined as all postmenopausal women with primary breast cancer diagnosed within the last 6 months. NB: This question does not apply to the provision of bisphosphonates for other indications, whether in breast cancer or another disease.

Yes

2. If you are routinely funding the provision of bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body, but have not defined your eligible population as all postmenopausal women with primary breast cancer diagnosed within the last 6 months, how have you defined your eligible population? For example, is it risk stratified.

Not applicable.

3. If you are routinely funding the provision of bisphosphonates to reduce the risk of primary breast cancer spreading to other parts of the body:

a. Which drug or drugs are you funding (e.g. zoledronic acid, ibandronate, clodronate)?

Ibandronate and zoldedronic acid

b. What proportion of patients receiving treatment with bisphosphonates are receiving zoledronic acid (regardless of whether they have received it once, or for the whole course of the treatment)?

The CCG dos not have this information at present as the pathway is at early stage of implementation.

4. If you are not routinely funding the provision of bisphosphonates to reduce the risk of primary  breast cancer spreading to other parts of the body:

a. What are your reasons for not doing so

b. Have you considered doing so, and who was involved in this decision-making process

Not applicable.

 

Part B – Faslodex (fulvestrant)

5. Is your CCG routinely funding Faslodex (fulvestrant) for women with hormone receptor positive locally advanced and metastatic breast cancer?

Yes.  This is available as treatment option.

 

6. If you are not routinely funding the provision of Faslodex (fulvestrant) for women with hormone receptor positive locally advanced and metastatic breast cancer:

a. What are your reasons for not doing so

b. Have you considered doing so, and who was involved in this decision-making process?

Not applicable.

 

Part C – Reconstructive breast surgery – procedure limits

7. Does your CCG have any policy or guidance in place that means that reconstructive breast surgery for breast cancer is procedure limited? This means that there is a limit on the number of reconstructive surgical procedures that a breast cancer patient can have. 

The CCG does not have a specific policy or guidance that limits reconstructive breast surgery; this is part of the cancer pathway if deemed appropriate for the patient.

8. If your CCG has a policy or guidance in place limiting the number of reconstructive surgical procedures that a breast cancer patient can have:

a. Please provide a copy of the policy or guidance, or details of it.

b. How long has the policy or guidance been in place?

Not applicable.

9. If your CCG does not have a policy or guidance in place limiting the number of reconstructive surgical procedures that a breast cancer patient can have:

a. Has it had any discussions on introducing such a policy or guidance?

b. Does it plan to introduce such a policy or guidance in the future?

There have been no discussions on introducing a policy or guidance at this time.

 

Part D – Reconstructive breast surgery – time limits

10. Does your CCG have any policy or guidance in place that means that reconstructive breast surgery for breast cancer is time limited? This means that a patient can only have reconstructive surgery for breast cancer within a certain period of time.

The CCG does not have a specific policy or guidance that imposes time limits for reconstructive breast surgery; this is part of the cancer pathway if deemed appropriate for the patient.

11. If your CCG has a policy or guidance in place putting a time limit on reconstructive breast surgery for breast cancer:

a. Please provide a copy of the policy or guidance, or details of it.

b. How long has the policy or guidance been in place?

Not applicable.

12. If your CCG does not have a policy or guidance in place putting a time limit on reconstructive breast surgery for breast cancer:

a. Has it had any discussions on introducing such a policy or guidance

b. Does it plan to introduce such a policy or guidance in the future?

There have been no discussions on introducing a policy or guidance at this time.

13. Does your CCG have any policy or guidance in place restricting balancing breast surgery for breast cancer patients? Balancing breast surgery is when surgery is undertaken on the opposite breast (to that which was treated for breast cancer) in order to make the breasts symmetrical.

The CCG does not have a specific policy or guidance that limits balancing breast surgery; this is part of the cancer pathway if deemed appropriate for the patient.

14. If your CCG has a policy or guidance in place restricting balancing breast surgery for breast cancer patients:

a. Please provide a copy of the policy or guidance or details of it.

b. How long has the policy or guidance been in place?

Not applicable.

15. If your CCG does not have a policy or guidance in place restricting balancing breast surgery for breast cancer patients:

a. Has it had any discussions on introducing such a policy or guidance?

b. Does it plan to introduce such a policy or guidance in the future?

There have been no discussions on introducing a policy or guidance at this time.

NHS Choices
NHS Constitution
NHS Constitution
Disability Confident Employer Badge

NHS Calderdale Clinical Commissioning Group: 5th floor, F Mill, Dean Clough, Halifax, HX3 5AX. Tel: 01422 307400

| Accessibility | Privacy Notice | Glossary of Terms | Work for us |

Icons provided by Icons8. Free Stock Videos by Videezy

© NHS Calderdale CCG 2019